Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
Hims & Hers Health Shares Tumble as its Weight-Loss Treatments Face Tough Environment
Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...
pharmaphorum6m
Lilly launches discounted high-strength Zepbound vials in US
Lilly recently revised its revenue forecast for 2024 after seeing weaker-than-expected growth for Zepbound and diabetes brand ...
pharmaphorum9m
Lilly launches discounted Zepbound vials in US
Lilly recently revised its revenue forecast for 2024 after seeing weaker-than-expected growth for Zepbound and diabetes brand ...
Eli Lilly rolls out new Zepbound vial versions on LillyDirect
Eli Lilly (NYSE:LLY) announced Tuesday it expanded its weight loss drug offerings, launching new 7.5 mg and 10 mg single-dose ...